The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRME | +74.35% | N/A | N/A | -74% |
| S&P | +17.45% | +75.43% | +11.88% | +84% |
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $838.00K | -61.6% |
| Gross Profit | -$1,038.00K | -322.7% |
| Gross Margin | -123.87% | -145.2% |
| Market Cap | $626.37M | 63.5% |
| Market Cap / Employee | $4.29M | 0.0% |
| Employees | 146 | -31.8% |
| Net Income | -$46,079.00K | -9.0% |
| EBITDA | -$46,732.00K | -9.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $63.03M | -65.5% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $108.29M | 191.3% |
| Short Term Debt | $8.14M | 125.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.35% | 12.2% |
| Return On Invested Capital | -72.40% | -7.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$37,546.00K | -359.8% |
| Operating Free Cash Flow | -$37,256.00K | -329.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.70 | 3.03 | 12.24 | 3.87 | 91.32% |
| Price to Sales | 67.72 | 64.32 | 148.77 | 135.23 | 16.48% |
| Price to Tangible Book Value | 1.70 | 3.03 | 12.24 | 3.87 | 91.32% |
| Enterprise Value to EBITDA | -4.68 | -6.54 | -15.24 | -12.09 | 161.36% |
| Return on Equity | -115.2% | -154.8% | -112.3% | -146.8% | 7.26% |
| Total Debt | $121.15M | $119.74M | $118.14M | $116.43M | 185.40% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
